Results 121 to 130 of about 172,741 (147)

Engineered red blood cell extracellular vesicles for delivery of Dox and siIDO1 enhance targeted chemo-immunotherapy of acute myeloid leukemia. [PDF]

open access: yesJ Immunother Cancer
Liu Y   +15 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT

Journal of Cancer Research and Clinical Oncology, 2007
Dendritic cell (DC)-based cancer vaccines are currently being evaluated as novel anti-tumor vaccination strategies, but in some cases, they are demonstrated to have poor clinical efficacies than anticipated. A potential reason is immune tolerance due to the immunosuppressive enzyme, indoleamine-pyrrole 2,3-dioxygenase (IDO).
Xueling Ou, Xinyao Wu, Shaohui Cai
exaly   +3 more sources

Indoleamine-pyrrole 2,3-dioxygenase

1994
Dietmar Schomburg, Dörte Stephan
exaly   +2 more sources

Homology Modeling of Human Indoleamine-Pyrrole 2,3-Dioxygenase-2 (hIDO2) and Virtual Screening Approaches to Identify Novel, Potent, and Selective HIDO2 Inhibitors

Palestinian Medical and Pharmaceutical Journal, 2023
Indoleamine 2,3-dioxygenase 2 (IDO2) is a newly discovered target proposed to be a promising therapeutic modulator of various peripheral and central pathological states such as autoimmune disorders and immune escape diseases like cancer. The lack of potent hIDO2 inhibitors presents a high demand for discovering novel hIDO2 inhibition strategies to ex ...
Şüküroğlu, Murat, Qaoud, Mohammed
openaire   +2 more sources

Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta

open access: yesJournal of Reproductive Immunology, 2004
Studies in mice have suggested that the placenta is protected from immune rejection by maternal T cells by means of localised indoleamine 2,3-dioxygenase dependent depletion of tryptophan.
Yoshiki Kudo   +2 more
exaly   +2 more sources

Abstract 3847: Creating the tumor microenvironment for effective immunotherapy: Antitumor activity of intratumoral IMO-2125, a TLR9 agonist is further enhanced by inhibition of indoleamine-pyrrole 2,3-dioxygenase (IDO)

Cancer Research, 2016
Abstract In recent years, understanding of tumor immunology has led to significant advances in cancer immunotherapy. New approaches include selective blockade of checkpoints, harnessing tumor infiltrating lymphocytes (TILs) and use of intratumoral oncolytic viruses.
Daqing Wang   +5 more
openaire   +1 more source

Home - About - Disclaimer - Privacy